# Rellergen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rellergen

- Industry: Biotechnology
- Headquarters: Xiamen, China
- Latest round: Series A (Jan 10, 2022)
- Investors on record: 3

## About

Established in 2016 and based in Xiamen, China, Rellergen is a biotechnology company that provides diagnostic solutions for allergy and autoimmune diseases. Rellergen completed tens of millions yuan in Pre-A round financing.

Rellergen is committed to providing diagnostic solutions for the diagnosis of allergies and autoimmune diseases based on the development, production and application promotion of microfluidic chip detection technology. The company established a high-performance and high-throughput technology platform that takes microfluidic technology as the core, combines technologies of protein coating and chemiluminescence detection. This platform aimed to provide more accurate and efficient detection solutions for clinical medicine and biological research. First application of the platform was to detection of allergen slgE. It only takes 100ul of serum samples to finish all 39 product testing procedures in clinical registration in 35 mintues.

Rellergen is going to accelerate clinical registration, realize the localization of key materials and accelerate the development of new products and technology platforms.

## Funding rounds

- Series A, Jan 10, 2022 — Dynamic Capital, Riverhead Capital, Yinglian Health Industry Fund

## Investors

- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series A
- Riverhead Capital (https://capitalatlas.ai/funds/riverhead-capital) — Series A
- Yinglian Health Industry Fund — Series A